Steve Rommel, TEVA, will speak at The 3D Medicine & Pharmaceutical Printing Conference which will take place on Feb 01, 2017 at MECC Maastricht in The Netherlands.
About Steve Rommel
Studied Woodtechnology & WoodProcessing In Rosenheim (Germany), 2001 – 2008 in Automotive (Supplier) in US leading technology development projects – 2006-2008 head of R&D, 2008-2016 Fraunhofer IPA in Stuttgart – working in technology risk assessment, 2011 – 2016 hear of 3D printing research group, 04/2016 TEVA Global Technology Center
Teva is committed to increasing access to high-quality healthcare for people across the globe, at every stage of life. We do this by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.
The company’s line of generic and specialty treatments is backed by our impressive global development and manufacturing capabilities, ensuring the highest quality and accessibility to medicines while reducing costs. Teva’s participation in a wide range of therapeutic areas and dosage forms is empowered by a unique integration of innovative specialty and generic research.